MYCOVACC
The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC)
Updates
June 21, 2023 – $2M Awarded to MYCOVACC for Expanding the Study of COVID-19 mRNA Vaccines
MYCOVACC has received a $2M boost from the Public Health Agency of Canada to expand and extend follow-up on patients with myocarditis and/or pericarditis after COVID-19 mRNA immunization or COVID-19 infection, and to do cardiac imaging on those affected.
The pan-Canadian study will receive an additional two years of funding, bringing the total investment in this important initiative to $3.6M over three years. Read the news release.
October 27, 2022 – CCS awarded $1.6M to study myocarditis and/or pericarditis following mRNA COVID-19 vaccination
In October 2022, the Public Health Agency of Canada awarded $1.6 million to the Canadian Cardiovascular Society to support a pan-Canadian study of the clinical and functional outcomes of adults and children who experienced myocarditis and/or pericarditis after receiving an mRNA COVID-19 vaccination.
CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) will provide critical information to support informed decision-making about vaccination and guide public health agencies in development of vaccine programs for boosters and new variants. Read the news release.
Join the MYCOVACC study
The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across the country to contribute to this multi-centre study. Study participants will be assessed at three months and 12 months after diagnosis and then annually for up to three years by a participating specialist using a clinical protocol based on the CCS 2021 Clinical Practice Update. They will also be invited to complete quality of life, mental health, physical activity, and health outcomes questionnaires.
To learn more about MYCOVACC: mycovacc@ccs.ca.
Newsletters
Videos
Dr. Nat Hawkins, MYCOVACC Scientific Lead, speaks about MYCOVACC at the 2022 Canadian Cardiovascular Congress.
Watch: Canadian Cardiovascular Society Leading a Renaissance in Myocarditis Research and Policy
This Canadian Cardiovascular Congress 2022 session introduces MYCOVACC to the Canadian cardiovascular community. Dr. Peter Liu and Dr. Sean Virani chair the session. The presenters are Dr. Tahir Kafil, Susanna Ogunnaike-Cooke, Carolyn Pullen, and Dr. Nat Hawkins.
Governance
The MYCOVACC governance structure aims to facilitate the participation and collaboration of CCS members, CCS Affiliate societies, investigators, and patients in study activities.
Steering Committee
The MYCOVACC Steering Committee is chaired by Dr. Nathaniel Hawkins. It includes CCS members as well as representatives from key partner networks and the Public Health Agency of Canada.
Resources
In 2021, the CCS developed COVID-19 resources and guidance documents for cardiovascular professionals and their patients. These documents can be accessed here: https://ccs.ca/covid-19-resources/.
MYCOVACC funding is supporting updates to these resources.
The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.